ALK-Abelló A/S/DKr ALK B
1D1W1MYTD1Y5YMAX
Capital at risk
About ALK-Abelló A/S
ALK-Abelló A/S is a pharmaceutical company engaged in the development and production of allergy immunotherapy products. Based in Hørsholm, Denmark, the company specializes in allergy treatments that include tablets, injections, and drops targeting common allergens such as grass, tree, and ragweed pollen, as well as house dust mites. Established in the early 20th century, ALK-Abelló has expanded its operations to serve markets globally, with a particular focus on Europe and North America. Its strategic advantage lies in its strong research capabilities and a comprehensive portfolio of allergy treatment options. The company's ongoing investment in innovation supports its goal to transform the treatment of allergies worldwide.
- Ticker
- DKr ALK B
- Sector
- Health
- Primary listing
- CSE
- Employees
- 2,773
- Headquarters
- Horsholm, Denmark
- Website
- www.alk.net
ALK-Abelló A/S Metrics
BasicAdvanced
kr 43B
31.60
kr 6.10
0.71
kr 1.60
0.83%
Price and volume
Market cap
kr 43B
Beta
0.71
52-week high
kr 271.40
52-week low
kr 191.80
Average daily volume
232K
Dividend rate
kr 1.60
Financial strength
Current ratio
3.457
Quick ratio
2.087
Long term debt to equity
0.052
Total debt to equity
0.061
Dividend payout ratio (TTM)
26.18%
Interest coverage (TTM)
183.50%
Profitability
EBITDA (TTM)
2,095
Gross margin (TTM)
68.18%
Net profit margin (TTM)
19.86%
Operating margin (TTM)
26.87%
Effective tax rate (TTM)
26.58%
Revenue per employee (TTM)
kr 2,460,000
Management effectiveness
Return on assets (TTM)
12.75%
Return on equity (TTM)
21.21%
Valuation
Price to earnings (TTM)
31.6
Price to revenue (TTM)
6.27
Price to book
6.15
Price to tangible book (TTM)
8.26
Price to free cash flow (TTM)
23.775
Free cash flow yield (TTM)
4.21%
Free cash flow per share (TTM)
8.105
Dividend yield (TTM)
0.83%
Forward dividend yield
0.83%
Growth
Revenue change (TTM)
16.52%
Earnings per share change (TTM)
36.38%
3-year revenue growth (CAGR)
13.42%
10-year revenue growth (CAGR)
8.66%
3-year earnings per share growth (CAGR)
55.75%
10-year earnings per share growth (CAGR)
11.69%
10-year dividend per share growth (CAGR)
20.40%
Bulls say / Bears say
ALK delivered 18% revenue growth and 19% EBIT growth in Q2, while first-half free cash flow reached DKK 889 million. Management also raised the lower end of its 2026 revenue-growth outlook to 14%, supporting the case that momentum is broad and cash-generative. (Inderes)
NICE recommendations for ALK’s tree-pollen and house-dust-mite tablets expand reimbursed access to children through the UK health system. That creates a larger eligible patient pool and should support further tablet adoption. (Inderes)
ALK’s positive phase 2 peanut-allergy trial gives it a potential new growth platform beyond respiratory allergies. The company plans to move into phase 3, subject to regulatory feedback on the final trial design. (GlobeNewswire)
Growth is not yet translating into clear operating leverage: Q2 gross-margin gains were offset by higher sales, marketing and other strategic investment, leaving the EBIT margin unchanged at 25%. Full-year EBIT-margin guidance is only around 26%, so spending could continue to limit earnings conversion. (Inderes)
The peanut opportunity remains a development project rather than a commercial product. Phase 3 is still planned for late 2026 and depends on further discussions with regulators, leaving scope for trial-design, timing or approval setbacks. (GlobeNewswire, Inderes)
Product mix and pricing remain risks to profitability. Management expects lower-margin partner-related revenue from China and Japan, as well as neffy sales, while its earlier outlook still allowed for price and rebate pressure and weaker growth in SCIT and SLIT-drop products. (Roic AI, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
Upcoming events
No upcoming events
Funds containing ALK-Abelló A/S
AllEURGBPUSD
Fund name | Fund size | DKr ALK B weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.25% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.25% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 0.21% |
Amundi STOXX Europe 600 ESG€C6E | €735M | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.